Health Loss Due To Market Access Delays And Reimbursement Restrictions In First-Line EGFR-Positive Non-Small Cell Lung Cancer In The EU5 Countries
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.376
https://www.valueinhealthjournal.com/article/S1098-3015(17)30710-6/fulltext
Title :
Health Loss Due To Market Access Delays And Reimbursement Restrictions In First-Line EGFR-Positive Non-Small Cell Lung Cancer In The EU5 Countries
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30710-6&doi=10.1016/j.jval.2017.08.376
First page :
A465
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
353